APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

$42.66  +0.71 (1.69%)
As of 05/27/2022 15:59:58 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/09/2017
Outstanding shares:  106,521,818
Average volume:  1,124,500
Market cap:   $4,355,677,138
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYTQ6X1

---

Valuation   (See tab for details)

---

PE ratio:   -6.37
PB ratio:   9.66
PS ratio:   53.81
Return on equity:   -151.79%
Net income %:   -866.81%